Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Animal studies

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    23 result(s) found for: Animal studies. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2009-011784-37 Sponsor Protocol Number: FORSS-37511 Start Date*: 2009-09-17
    Sponsor Name:Department of Orthopaedics IKE
    Full Title: Does teriparatide lower the risk for loosening of a knee prosthesis?
    Medical condition: Knee osteoarthritis. In animal studies teriparatide has shown a positive effect on fracture healing. So far, teriparatide (Forsteo ®) is only registrered for treatment of severe osteoporosis. A ce...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023849-30 Sponsor Protocol Number: CSCAbrein&cognitie1-04 Start Date*: Information not available in EudraCT
    Sponsor Name:University of Amsterdam
    Full Title: The effects of MR and GR blockade on the reconsolidation and extinction of fear memories
    Medical condition: Fear conditioning acquisition, reconsolidation and extinction in healthy male subjects.
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005026-21 Sponsor Protocol Number: 1403740 Start Date*: 2012-01-31
    Sponsor Name:KYTHERA Biopharmaceuticals, Inc.
    Full Title: Long-term, follow-up study of subjects who completed phase III trials ATX-101-10-16 or ATX-101-10-17 (sodium deoxycholate injection) for the reduction of localized subcutaneous fat in the submental...
    Medical condition: Reduction of subcutaneous fat in the submental area
    Disease: Version SOC Term Classification Code Term Level
    17.1 10018065 - General disorders and administration site conditions 10016251 Fat tissue increased PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-006227-38 Sponsor Protocol Number: 11.017 Start Date*: 2012-05-01
    Sponsor Name:Ove B. Schaffalitzky de Muckadell
    Full Title: “Assessment of fibrotic liver disease in a medical admission ward and intervention with losartan as antifibrotic therapy in patients with alcoholic liverdisease”
    Medical condition: Fibrotic alcoholic liver disease is in early stages often completely asymptomatic. Fully developed cirrhosis affect a wide range of physiological conditions. Eksamples are portal hypertension and f...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10019805 - Hepatobiliary disorders 10001627 Alcoholic liver disease PT
    14.1 10019805 - Hepatobiliary disorders 10001626 Alcoholic liver damage, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-000908-17 Sponsor Protocol Number: Siena Eye Cross Linking 2004 Start Date*: 2007-01-11
    Sponsor Name:AZIENDA OSPEDALIERA SENESE
    Full Title: Medical therapy of keratoconus with Riboflavin/Ultraviolet-A collagen Cross-Linking and investigation of the corneal stromal and Keratocytes modifications apoptosis and stromal repopulation with ...
    Medical condition: Patients affected by keratoconus worsening
    Disease: Version SOC Term Classification Code Term Level
    6.1 10023353 PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002692-34 Sponsor Protocol Number: MitoFibrateCT1-2012 Start Date*: 2013-06-26
    Sponsor Name:Univ.-Klinik für Kinder- und Jugendheilkunde
    Full Title: Clinical study for the assessment of safety and efficacy of Bezafibrate as a drug therapy for patients with mitochondrial myopathies
    Medical condition: mitochondrial disorder
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002109-22 Sponsor Protocol Number: 02/05/Hü Start Date*: 2005-12-01
    Sponsor Name:Medical University of Vienna
    Full Title: Comparative Effects of Telmisartan and Candesartan on glucose metabolism in patients with chronic heart failure
    Medical condition: both investigated drugs are well established in the treatment of heart failure or hypertension respectively. As the investigateed Patients have this conditions according to the inclusion criteria, ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2004-000333-10 Sponsor Protocol Number: GEN/231/51/BMcK/JCL Start Date*: 2004-12-15
    Sponsor Name:Research & Innovation Services, University of Dundee
    Full Title: The inhibitory effect of local anaesthetics on the G-protein-mediated vascular flare response to bradykinin and substance P
    Medical condition: Healthy volunteers
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-011485-28 Sponsor Protocol Number: MANAMI101-09 Start Date*: 2009-08-12
    Sponsor Name:PledPharma AB
    Full Title: A local feasibility study of mangafodipir as an adjunct to percutaneous coronary intervention in patients with acute myocardial infarction
    Medical condition: Patients with acute myocardial infarction decided for treatment by percutaneous coronary intervention (PCI) are included. The test drug mangafodipir is administered intravenously just prior to PCI....
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2008-003287-18 Sponsor Protocol Number: PET-FRAX-001 Start Date*: 2008-09-17
    Sponsor Name:University Antwerp [...]
    1. University Antwerp
    2. University Hospital Leuven gasthuisberg
    Full Title: Functional consequences of decreased RNA expression of certain GABA(A) receptor subunits in fragile X patients using Positron Emission Tomography and [11C]flumazenil.
    Medical condition: Fragile X syndrome is the most common form of inherited mental retardation with a prevalence of 1/4000 males and 1/6000 females. Patients are characterized by a mild to severe form of cognitive imp...
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001176-67 Sponsor Protocol Number: MEC-66108-2007 Start Date*: 2009-10-16
    Sponsor Name:Dr. Antonio Osuna Ortega
    Full Title: Biodisponibilidad de quercetina bajo distintas formas de administración y sus implicaciones sobre el efecto antihipertensivo
    Medical condition: Several epidemiologic studies have reported an inverse association between dietary flavonoid intake and mortality related to ischaemic heart disease. Our studies show that quercetin, the main dieta...
    Disease: Version SOC Term Classification Code Term Level
    9 10015489 Essential hypertension, benign LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-014344-11 Sponsor Protocol Number: prot-001-2009 Start Date*: 2010-06-02
    Sponsor Name:Imperial College London
    Full Title: Neuroprotective effects of hypothermia combined with inhaled xenon following perinatal asphyxia - the TOBY Xe trial
    Medical condition: Neonatal asphyxial encephalopathy
    Disease: Version SOC Term Classification Code Term Level
    12 10028946 neonatal hypoxia and asphyxia SOC
    Population Age: Newborns, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-001383-18 Sponsor Protocol Number: Start Date*: 2015-11-30
    Sponsor Name:University of Oxford
    Full Title: An open label Phase 2 clinical trial of retinal gene therapy for choroideremia using an adeno-associated viral vector (AAV2) encoding Rab-escort protein 1 (REP1)
    Medical condition: Choroideremia - a currently incurable retinal degeneration caused by null mutations in the CHM gene encoding REP1 protein located on the X chromosome. The condition causes blindness in males by the...
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004853 10008791 Choroideremia LLT
    Population Age: Adults Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2022-001958-36 Sponsor Protocol Number: SDX_01 Start Date*: 2022-08-29
    Sponsor Name:Corporativo de Servicios Médicos Especializados S.A de C.V V (Centro Médico del Noroeste)
    Full Title: Endothelial protection in convalecent COVID-19 patients. The effect of Sulodexide on serum levels of biomarkers for endothelial dysfunction. A prospective, randomized, placebo-controlled, investiga...
    Medical condition: Coronavirus disease 2019 (COVID-19) is an infectious disease caused by coronavirus 2 (SARS-CoV-2) and, thus, being a novel cause of sepsis and the the poor outcome of patients with sepsis was relat...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-003792-34 Sponsor Protocol Number: DIA-2-REDESIGN Start Date*: 2015-03-25
    Sponsor Name:GWT-TUD GmbH
    Full Title: RANDOMIZED DOUBLE BLIND PARALLEL DESIGN STUDY COMPARING RISK OF NOCTURNAL HYPOGLYCEMIA AND CRITICAL ARRHYTHMIAS WITH SITAGLIPTIN VERSUS GLIMEPIRIDE IN PATIENTS WITH TYPE 2 DIABETES INSUFFICIENTLY C...
    Medical condition: Patients with diabetes mellitus type 2 inadequately controlled on metformin monotherapy
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005061-13 Sponsor Protocol Number: A011-12 Start Date*: 2021-06-22
    Sponsor Name:Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA
    Full Title: An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH
    Medical condition: Pulmonary Arterial Hypertension (PAH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) SE (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) AT (Trial now transitioned) PT (Trial now transitioned) CZ (Trial now transitioned) DK (Trial now transitioned) GR (Trial now transitioned) HR (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2018-000027-14 Sponsor Protocol Number: T-19-11318v19 Start Date*: 2018-08-20
    Sponsor Name:Imperial College London
    Full Title: A Phase 2, Pilot Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment Chronic Active Antibody Mediated Rejection in Renal Transplantation
    Medical condition: Chronic active antibody mediated rejection of renal transplants
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10023439 Kidney transplant rejection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2012-003561-17 Sponsor Protocol Number: ECP-002 Start Date*: 2013-08-09
    Sponsor Name:Edimer Pharmaceuticals, Inc.
    Full Title: A Phase 2 open-label, dose-escalation study to evaluate the safety, pharmacokinetics, immunogeniticy and pharmacodynamics/efficacy of EDI200, an EDA-A1 replacement protein, administered to male inf...
    Medical condition: X-linked hypohidrotic ectodermal dysplasia (XLHED) is caused by inherited defects in the ectodysplasin (EDA) gene that disrupt synthesis and/or function of the primary translational product EDA-A1....
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004850 10072592 Hypohidrotic ectodermal dysplasia LLT
    Population Age: Newborns, Under 18 Gender: Male
    Trial protocol: DE (Completed) GB (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-001420-34 Sponsor Protocol Number: 0001 Start Date*: 2020-04-14
    Sponsor Name:Aarhus University
    Full Title: Senicapoc in COVID-19 Patients with Severe Respiratory Insufficiency – A Randomized, Open-Label, Phase II Trial
    Medical condition: Infection with COVID19
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001052 Acute respiratory distress syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-004740-30 Sponsor Protocol Number: PHRCN2018 Start Date*: 2021-09-15
    Sponsor Name:Centre Hospitalier Le Vinatier
    Full Title: Cannabidiol for reducing drinking in alcohol use disorder and modifying the effects of alcohol on the brain and the liver: a phase 2 clinical trial.
    Medical condition: CARAMEL is an exploratory phase-2 study conducted in subjects with AUD (alcohol use disorder) and current heavy drinking level, aiming to confirm the different properties of CBD observed in animal ...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10001590 Alcohol addiction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 28 01:17:49 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA